US Patent

US10383864 — Methods for treatment of Fabry disease

Method of Use · Assigned to Amicus Therapeutics Inc · Expires 2027-05-16 · 1y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.

USPTO Abstract

Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.

Drugs covered by this patent

migalastat-hydrochloride (MIGALASTAT HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2371`	—	migalastat-hydrochloride

Patent Metadata

Patent number: US10383864
Jurisdiction: US
Classification: Method of Use
Expires: 2027-05-16
Drug substance claim: No
Drug product claim: No
Assignee: Amicus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.